牛牛AI助理已提取核心訊息
Panbela Therapeutics, Inc. has announced the issuance of up to 21,857,923 shares of common stock, along with Class E and Class F Common Warrants to purchase an equivalent number of shares. Additionally, Pre-Funded Warrants to purchase up to 21,857,923 shares of common stock are being offered. Upon exercise of these warrants, a total of 65,573,769 shares of common stock could potentially be issued. The offering is being managed by Roth Capital Partners, LLC as the lead placement agent on a reasonable best efforts basis. The pricing and terms of the securities are subject to negotiation based on market conditions at the time of the offering. The company has entered into lock-up agreements restricting the sale of shares by company executives and directors for 90 days post-offering. The proceeds from the offering are intended for the continued clinical development of Panbela's product candidates, including ivospemin and eflornithine, and for general corporate purposes. The offering is subject to customary closing conditions and regulatory approvals.
Panbela Therapeutics, Inc. has announced the issuance of up to 21,857,923 shares of common stock, along with Class E and Class F Common Warrants to purchase an equivalent number of shares. Additionally, Pre-Funded Warrants to purchase up to 21,857,923 shares of common stock are being offered. Upon exercise of these warrants, a total of 65,573,769 shares of common stock could potentially be issued. The offering is being managed by Roth Capital Partners, LLC as the lead placement agent on a reasonable best efforts basis. The pricing and terms of the securities are subject to negotiation based on market conditions at the time of the offering. The company has entered into lock-up agreements restricting the sale of shares by company executives and directors for 90 days post-offering. The proceeds from the offering are intended for the continued clinical development of Panbela's product candidates, including ivospemin and eflornithine, and for general corporate purposes. The offering is subject to customary closing conditions and regulatory approvals.
Panbela Therapeutics, Inc.宣佈發行多達21,857,923股普通股，以及購買等量股票的E類和F類普通認股權證。此外，還發行了購買多達21,857,923股普通股的預融資認股權證。行使這些認股權證後，總共可能發行65,573,769股普通股。此次發行由作爲主要配售代理人的羅斯資本合夥人有限責任公司在合理的最大努力基礎上進行管理。證券的定價和條款有待根據發行時的市場狀況進行協商。該公司已簽訂封鎖協議，限制公司高管和董事在發行後的90天內出售股票。此次發行的收益將用於Panbela候選產品的持續臨床開發，包括依沃司培明和依氟鳥氨酸，並用於一般公司用途。此次發行須遵守慣例成交條件和監管部門的批准。
Panbela Therapeutics, Inc.宣佈發行多達21,857,923股普通股，以及購買等量股票的E類和F類普通認股權證。此外，還發行了購買多達21,857,923股普通股的預融資認股權證。行使這些認股權證後，總共可能發行65,573,769股普通股。此次發行由作爲主要配售代理人的羅斯資本合夥人有限責任公司在合理的最大努力基礎上進行管理。證券的定價和條款有待根據發行時的市場狀況進行協商。該公司已簽訂封鎖協議，限制公司高管和董事在發行後的90天內出售股票。此次發行的收益將用於Panbela候選產品的持續臨床開發，包括依沃司培明和依氟鳥氨酸，並用於一般公司用途。此次發行須遵守慣例成交條件和監管部門的批准。
有用
沒用